Human immunodeficiency virus and liver disease forum 2010: conference proceedings

Abstract

Liver disease continues to represent a critical mediator of morbidity and mortality in those with human immunodeficiency virus (HIV) infection. The frequent presence and overlap of concomitant injurious processes, including hepatitis C virus and hepatitis B virus infections, hepatoxicity associated with antiretroviral therapeutic agents, alcohol, and other toxins, in the setting of immunosuppression lead to rapid fibrotic progression and early development of end-stage liver disease. This conference summary describes the proceedings of a state-of-the-art gathering of international experts designed to highlight the status of current research in epidemiology, natural history, pathogenesis, and treatment of HIV and liver disease.

Fig. 1

2010 current treatment guidelines for preferred initial antiretroviral regimens for HIV/HCV-coinfected patients. Rating of recommendation: A = strong; B = moderate; C = optional. Rating of evidence: I = data from randomized, controlled trials; II = data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = expert opinion (www.aidsinfo.nih.-gov/guidelines; accessed on June 14, 2011).

Fig. 2

(A) Improvement in SVR in Caucasian naïve patients with TVR is greater with the IL-28b T allele. P, PEG-IFN; R, RBV; #, weeks of treatment; T, TVR. Figure created from data presented by Jacobson et al., EASL 2011. (B) Improvement in SVR in naïve patients with BOC is greater with the IL-28b T allele. P, PEG-IFN; R, RBV; #, weeks of treatment; RGT, response-guided therapy. Figure created from data presented by Poordad et al., at the 46th Annual Meeting of the International Liver Congress by the European Association for the Study of the Liver, March 30-April 3, 2011, Berlin, Germany.

Fig. 3

Higher week 12 response rates in HCV/HIV-coinfected patients in all groups taking TPV/Peg/R. Peg, PEG-IFN; R, RBV. Figure created from data presented by Sulkowski et al. at the 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, MA.